CAMBRIDGE, Mass. (TheStreet) -- The hepatitis C drug telaprevir from Vertex Pharmaceuticals(VRTX Quote) is working its way through phase III clinical trials and is widely expected to be the first new drug in years approved for the treatment of the chronic liver disease.
But how long can telaprevir maintain its "king of the mountain" status? And which drug, if any, will be the one to knock telaprevir from its perch? Questions like these form a recurring subplot for Wall Street twice a year when liver disease experts gather to present new research.
Boerhinger Ingelheim's BI-201335 (let's call it '335 for short) seems to be the telaprevir competitor receiving the most attention as Wall Street gears up for the American Association for the Study of Liver Disease annual meeting, Oct. 30 through Nov. 4. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,318.16 | 1,091.38 | 2,146.04 | 33.56 |
Oil *
77.53
|
|
DOWN
14.28
|
DOWN
3.52
|
DOWN
10.78
|
UP
0.07
|
10 Yr
3.36%
SPDR Gold
112.94
|
|
-0.14%
|
-0.32%
|
-0.50%
|
+0.21%
|
Data delayed 20 minutes |
Connect with TheStreet